Evidence map›Paper›PMID 41140759›Full record

ArticleGastro hep advances2026

Development of a Neural Network to Detect Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Masashi Hirooka, Teruki Miyake, Ryo Yano, Yoshiko Nakamura, Yuki Okazaki, Toyoki Shimamoto, Yasunori Yamamoto, Takao Watanabe, Osamu Yoshida, Kana Hirooka and 4 more

Abstract read
In one paragraph

Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Masashi HirookaTotal Medical Support Center, Ehime University Hospital, Toon, Japan.
Teruki MiyakeDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Ryo YanoDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Yoshiko NakamuraDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Yuki OkazakiDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Toyoki ShimamotoDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Yasunori YamamotoDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Takao WatanabeDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Osamu YoshidaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Kana HirookaDepartment of Gastroenterology and Metabology, National Hospital Organization Ehime Medical Center, Toon, Japan.
Yoshio TokumotoDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Masanori AbeDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Takeru IwataEhime General Health Care Association, Matsuyama, Japan.
Yoichi HiasaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Early identification of metabolic dysfunction-associated steatotic liver disease (MASLD) is critical for risk stratification and timely intervention. Conventional noninvasive indices (fatty liver index, hepatic steatosis index, Zhejiang University index, and MASLD index) are limited by linear assumptions and moderate predictive accuracy. We aimed to develop and externally validate a neural network model for noninvasive detection of hepatic steatosis. Methods: We used a retrospective cohort of 17,465 Japanese health checkup participants (2010-2020). All clinical data were obtained at the Ehime General Health Care Association. The cohort was split into a development cohort (n = 8426) and an internal validation cohort (n = 9039). A feedforward neural network was trained using clinical and biochemical variables, including body mass index, abdominal circumference, and existing indices. External validation used the Third National Health and Nutrition Examination Survey cohort (n = 9759), with hepatic steatosis defined by ultrasonography (Gallbladder and Upper Abdominal Ultrasound Hepatic Steatosis Profile Rating≥2). Model performance was assessed via area under the receiver operating characteristic curve, calibration, decision curve analysis, and subgroup analyses. Results: The neural network achieved an area under the receiver operating characteristic curve of 0.922 (95% confidence interval: 0.913-0.931) in internal validation and 0.924 (95% confidence interval: 0.917-0.931) in external validation, outperforming fatty liver index, hepatic steatosis index, Zhejiang University index, and MASLD indices (all Conclusion: Our neural network model outperforms conventional indices in detecting moderate-to-severe hepatic steatosis and may facilitate early, scalable MASLD screening in primary care and low-resource settings.UMIN No. 11953.

Indexed as

artificial intelligencehepatic steatosismetabolic dysfunctionneural network modelnoninvasive screening

Identifiers

PMID41140759
PMCPMC12546783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.